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Abstract 
Alzheimer’s Disease (AD) is a highly complex disease involving a broad range of clinical, cellular, and 
biochemical manifestations that are currently not understood in combination. This has led to many 
views of AD, e.g. the amyloid, tau, presenilin, oxidative stress, and metal hypotheses. The amyloid 
hypothesis has dominated the field with its assumption that buildup of pathogenic β-amyloid (Aβ) 
peptide causes disease. This paradigm has been criticized, yet most data suggest that Aβ plays a key 
role in the disease. Here, a new loss-of-function hypothesis is synthesized that accounts for the 
anomalies of the amyloid hypothesis, e.g. the curious pathogenicity of the Aβ42/Aβ40 ratio, the loss of 
Aβ caused by presenilin mutation, the mixed phenotypes of APP mutations, the poor clinical-
biochemical correlations for genetic variant carriers, and the failure of Aβ reducing drugs. The 
amyloid-loss view accounts for recent findings on the structure and chemical features of A variants 
and their coupling to human patient data. The lost normal function of APP/Aβ is argued to be metal 
transport across neuronal membranes, a view with no apparent anomalies and substantially more 
explanatory power than the gain-of-function amyloid hypothesis. In the loss-of-function scenario, the 
central event of Aβ aggregation is interpreted as a loss of soluble, functional monomer Aβ rather than 
toxic overload of oligomers. Accordingly, new research models and treatment strategies should focus 
on remediation of the functional amyloid balance, rather than strict containment of A, which, for 
reasons rationalized in this review, has failed clinically. 
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Introduction 
As this is written, every day brings approximately 4000 new cases of Alzheimer's Disease (AD) to the 
world: Approximately 28−33 million people world-wide suffer from AD[1][2]; in 2010, 21−25 million 
AD cases were estimated[3] (60−70% of 35.6 million dementia cases), suggesting an annual growth of 
~1.5 million cases.  
The disease is terrifying to patients and relatives as the gradual loss of memory and identify 
leads to a slow but steady degeneration of life quality, and the societal costs of AD constitutes a major 
challenge to healthcare budgets[4][5]. Current treatments delay disease progression by only some 
months[4][6], and the recent failures of clinical trials of leading drug candidates have been a major 
concern[7][8][9][10][11][12][13].   
 AD first manifests slowly, starting with mild cognitive impairment[14][15][16], then leads to 
gradual loss of cognitive skills, identity, and activity[17][18]. The loss of neurons takes place primarily 
in the cerebral cortex and in the hippocampus[19]. Definitive AD diagnosis includes deposits of senile 
plaques outside the neurons and neurofibrillar tangles inside them as two major hallmarks of this 
disease[16][18]. The senile plaques consist of oxidized and metal-bound β-amyloid (Aβ) peptides 
organized as regular β-sheet-structured fibrils[20][21]. The neurofibrillar tangles consist primarily of 
phosphorylated tau protein[22][23]. AD patients also bear marks of massive molecular oxidative 
stress[24], impaired glucose utilization[25][26], diabetes-like pathologies[26][27], and imbalances in 
metal ion levels, such as calcium[28][29][30], iron[31][32], zinc[19][33][34], and copper[35][36].   
 The failure to efficiently treat AD directly relates to the fact that AD is a complex, multi-factor 
late-onset neurological disease: Approximately 95% of AD cases occur with no apparent family history 
as so called "sporadic AD" (SAD); only about 5% of emerging AD cases can be related to a family 
history, i.e." familial AD" (FAD)[37]. The complexity is further reflected in the very broad clinical 
spectrum of the disease with multiple cognitive, as well as histopathological manifestations[16], the 
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highly variable clinical features and survival times[9], and the notable fact that age, not any particular 
gene or event, is the main risk factor of the disease[38], whereas a large range of minor genetic, life-
style, and environmental risk modifiers contribute to overall disease risk[39][40].  
 This complexity and the many histopathological aspects of the disease have produced a range of 
hypotheses on the underlying causes of AD (see Figure 1): Focus on the biomolecular changes have 
led to several "post-translational" hypotheses on the causes of AD focusing on these features[19], e.g. 
the tau[41][42][43][44], metal ion[45][46] and oxidative stress[47][48] hypotheses. These hypotheses 
supplement the genetics-supported amyloid and presenilin hypotheses to be discussed below and the 
early cholinergic hypothesis that emphasized the direct impairment of pathways involving 
acetylcholine-rich neurons[49][50]. As will be discussed in this review, these hypotheses are not 
contradictory but rather convey specific pieces of information that, when put together in context, 
provides a unique and consistent picture of the true nature of the disease.  
In terms of genetic risk, FAD has been related to variations in the genes coding for the amyloid 
precursor protein (APP)[51] and the presenilin isoforms PSEN1 and PSEN2[52][53][54][55][56]. Thus, 
APP and PSEN have been the central frameworks of AD research, leading to two "gene-centric" 
hypotheses of AD etiology: the amyloid hypothesis[20][57][58] and the presenilin hypothesis[59][60]. 
In addition, the apolipoprotein E ε4 allele (ApoE4) increases risk by several times for heterozygote 
carriers and by up to 15-fold for homozygotes[61][62][63]. The sorting protein-related receptor 
(SORL1 or LR11) has been suspected of being involved in AD for more than a decade[64], and was 
found to be downregulated in AD [65]. It relates to APP and Aβ trafficking, and lipid metabolism (it 
works as a ApoE receptor), putting it in possible relation to other genetic risk factors[66]. In 2007, its 
gene SORL1 was identified as a likely risk factor of AD[67][68]. Genome-wide association studies 
(GWAS) have identified a range of other variations that may increase risk of AD[69][70], e.g. GAB2, 
GALP, TNK1, TREM2, PICALM, and CLU[54][70][71][72][73].  
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Figure 1. Simplified overview of the biochemistry of Alzheimer's disease. Previously proposed 
mechanistic hypotheses are shown in orange and key pathologies in red. APP, PSEN, and Aβ are 
shown as light blue, green, and yellow, respectively, and metal ions are shown as small green or blue 
circles. The gain-of-function amyloid hypothesis dominates the left of the figure, and alternative 
hypotheses are located to the right.  
 
Some established life-style-related risk modifiers are body mass index[74][75][76][77], 
smoking[78] [79], alcohol intake[80][81][82], diabetes[27][83], hypertension[84], depression[85][86], 
and overall (both mental and physical) inactivity[87][88][89]. Some risk modifiers reduce risk of AD, 
including mental and physical activity (e.g. education)[39][90][88], anti-oxidant and vitamin rich 
diets[39][91][92][93][94]. Several of these risk modifiers probably correlate, so that in summary, an 
active, healthy, and positive life style reduces risk of AD. 
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The amyloid hypothesis: Gain of toxic Aβ function 
The senile plaques characteristic of AD have been a natural starting point for understanding the 
disease: The parallel of protein deposits to Creutzfeldt-Jakob disease led to the original hypothesis that 
these plaques in AD might be pathogenic[95]. When these plaques were found to contain large amounts 
of Aβ peptides, the basis for the amyloid hypothesis was established[96]. Representative structures of 
the Aβ monomer in water and the β-sheet-structured aggregates characteristic of senile plaques are 
shown in Figure 2 A and Figure 2B, respectively. Subsequently, it was found that Aβ is produced 
from APP by the action of β- and γ-secretases[97][98], and moreover, that PSEN is the catalytic unit of 
the γ-secretase[99][100][101], which also cleaves other important substrates such as Notch[102][103]. 
Thus, the two major genetic risks of FAD, PSEN and APP, suggested a role of Aβ and supported the 
dominating paradigm of AD, the amyloid hypothesis[20][57][104].  
 The amyloid hypothesis is a "gain-of-function" hypothesis, i.e. it proposes that Aβ attains a 
toxic function in the brain that leads to disease[11][57]. In its early form, referred to as the "amyloid 
cascade hypothesis", it was a quantitative gain-of-function hypothesis, i.e. it was assumed that the 
steady state levels of Aβ were toxic in themselves, and that these levels were increased gradually 
during progression of AD[20][104]. This "overload" etiology would provide an explanation for the vast 
Aβ deposits in brains that typically represent several years of total Aβ production[105].  
 However, various observations were not consistent with a cascade of quantitative build-up as 
the main culprit of AD: First, neuro-degeneration and cognitive decline does not correlate significantly 
with plaque A load[6,11], implying that the plaque load is not a characteristic feature of disease 
severity. Neuron loss generally begins in specific parts of the brain (e.g. hippocampus) although A is 
found across the brain[106][107]. Also, a substantial fraction (perhaps 20−40%) of cognitively normal 
older people have A plaques[108] that would satisfy commonly applied AD diagnosis 
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criteria[109][110]. It has been suggested that these deposits in normal people represent pre-clinical 
disease states[111], but more likely, the plaques are not involved themselves in the pathogenesis, 
because they are insoluble and outside the cells: Instead, intracellular soluble oligomers of Aβ, not 
fibrils as found in plaques, are the most toxic forms of the peptide[112][113][114][115][116]. Plaques 
might then in fact be indicators of a protective pathway whereby Aβ is exported from cells and 
aggregates into fibrils, to reduce the burden of intracellular oligomers[117][118]. 
 FAD-related mutations in PSEN1 often do not lead to higher, but lower A levels measured in 
cultured cells[97][119], which is  not consistent with quantitative gain-of-function[9]. The Aβ peptides 
produced by cleavage of APP vary in length, with the two dominating isoforms, Aβ40 and Aβ42, having 
40 and 42 amino acids, respectively[9][119]. The APP intracellular domain (AICD) fragment produced 
simultaneously thus also changes size[120]. Interestingly, PSEN1 mutations generally increase steady-
state Aβ42/Aβ40 isoform ratios, which is therefore now considered the relevant culprit by proponents of 
the amyloid hypothesis[58][121]. The longer amyloid isoforms have additional hydrophobic amino 
acids in their C-terminal part and are thus more hydrophobic and prone to aggregation[122][123], and 
accordingly also more toxic in cell viability assays as these features correlate[20][118][124].  
 The measured cell toxicity of Aβ oligomers is very structure-dependent[125][126][127], and it 
has not yet been possible to identify the specific disordered structural forms of the peptide that 
allegedly causes AD[128][129], although recently, specific structural features have been found to 
correlate with toxicity[124]. A number of mechanisms have been suggested[130], such as impairment 
of long-term potentiation[131] and oxidative stress caused by the peptides[132]. Aβ forms membrane 
channels that facilitate calcium transport[133][134][135][136]. The calcium dyshomeostasis thereby 
caused by Aβ is a potential mode of pathogenicity[29][30][135][137]. Aβ may also interrupt copper-
mediated prion-protein interaction with NMDA receptors [138] and impair the respiratory chain in 
mitochondria[139][140][141][142].  
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Figure 2. A) The disordered structure of monomeric Aβ40 in water (PDB: 2LFM)[143]. B) The regular 
β-sheet structure of Aβ aggregates characteristic of senile plaques (PDB: 2MXU)[144] (Figures were 
produced using the Pymol software). 
 
 The quantitative amyloid hypothesis is thus being abandoned in favor of a "qualitative" gain-of-
function hypothesis centering on the A42/A40 ratio[10][119]. As most FAD-causing mutations 
increase this ratio[145][146][147][148], it could indeed be pathogenic. The increase in this ratio is 
probably caused by the fact that γ-secretase cleavage of APP proceeds towards the N-terminal of A in 
consecutive steps of 3−4 amino acids[149] and the FAD mutations are likely to affect the precision of 
this step-wise cleavage[150][151]. PSEN1 mutations tend to be dominant, i.e. heterozygote carriers are 
likely to develop AD, which has been taken to support a gain-of-toxic function as the compensatory 
presence of the wild type does not prevent disease[119].  
 The recent electron microscopy structure of γ-secretase shows details of PSEN1 having a 
transmembrane helix topology[152][153]. Although the loops are missing in the experimental structure, 
loops and other missing atoms have been included in full structural-dynamic models in physiologically 
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relevant membrane environments[154][155] (see Figure 3A and Figure 3B for full atomic structures 
of PSEN1 [155] modeled from the 2015 electron microscopy topology[153]). The interior space around 
the active site constituted by two catalytic aspartates is sensitive to long-range motions caused by 
dynamic membrane packing effects and loop motions that function as plugs in the transmembrane 
channel that open access to PSEN1's active site[155]. The gate-plug mechanism suggests that PSEN1 
mutations impair membrane packing and thereby substrate selectivity by reducing the steric control of 
the catalytic site, leading to reduced cleavage precision and increased A42/A40 ratios[155]. This 
mechanism can be directly coupled to clinical outcome: Clinical age of symptom onset of patients 
carrying PSEN1 variants correlate significantly with increased polarity and loss of stability of the 
protein[156], consistent with PSEN1 membrane structural integrity as a determining feature of PSEN1-
variant caused FAD.  
 In line with the amyloid hypothesis, drugs have been pursued that prevent the formation of 
amyloid oligomers, the assumed pathogenic species[157], either by direct molecular interaction with 
Aβ[158][159][160] or by inhibition of its production[161][162]. Given the potential mechanistic 
relationship between catalytic proficiency of γ-secretase and the A42/A40 ratio, inhibiting γ-secretase 
could create phenotypes that resemble the FAD-causing mutants; thus, it is hardly surprising that such 
inhibitors can produce adverse cognitive effects in human clinical trials[13][163]. Instead, modulation 
of the produced relative A42/A40 levels is now pursued as one of main clinical strategies in the form 
of so-called -secretase modulators[97][119][161].  
10 
 
 
Figure 3. All-atom structure of mature presenilin 1 with loops from homology models and molecular 
dynamics simulations[155], based on the partial presenilin coordinates of the 2015 electron microscopy 
structure of γ-secretase[153]. A) Seen from the in-membrane perspective; B) seen from the above-
membrane perspective. The catalytic aspartate residues D257 and D385 are shown in red. The loops 
play a major role in controlling access to the protein's interior. 
 
Challenging the amyloid hypothesis 
Recently, the A42/A40 ratio and specific chemical properties of PSEN1 mutants have been shown to 
correlate significantly with clinical symptom onset[156], providing a first relationship between human 
AD and protein-chemical features, which complements data from cell and mouse models that provide 
poor correlations to clinical data in meta-analysis[9] and in the transition to human trials[7][163]. Yet, 
correlation does not imply causation, and a complex disease such as AD features many apparent 
correlations. One example is the Aβ42/Aβ40 ratio: While this ratio does indeed correlate inversely with 
human symptom onset for the PSEN mutations[156], it does not for the phenotype-wise mixed APP 
mutations[9], and the increased ratio in PSEN mutant phenotypes could thus simply be a reflection of 
the loss of function of PSEN as the true cause of disease. Thus, all relevant correlations and equally 
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well all lack of correlations must be viewed in their totality. More generally, the following issues 
challenge the amyloid gain-of-function hypothesis:  
 First, it remains unclear how the curious A42/A40 ratio defines disease, while total levels of 
A42 do not (total levels tend to decrease or change insignificantly in PSEN1 mutant 
phenotypes[9][148]). Presumably, higher A42/A40 ratios either lead to more oligomers or impart 
them with more sinister properties, yet how can the ratio, but not A42 alone, produce such an effect? 
Lower overall production of A caused by PSEN1 mutation does not necessarily imply lower steady-
state levels of the presumed pathogenic oligomers, if oligomer clearance rates are lowered even more. 
Both A42 and A40 clearance has been found to be reduced by 30% in SAD, while production was 
unaffected[164]. This could imply that steady-state A pools are increased in SAD, but this is 
inconsistent with the reduced levels seen in PSEN1 mutants[146]. Thus, it probably rather reflects the 
increase in degradation-resistant plaques, whereas intracellular soluble A may have decreased: This 
would explain the lower clearance rates measured and reconcile the data discussed above.  
 The oligomers may be more degradation resistant than monomers, but probably less than the 
tightly bound β-sheets of plaques. The amyloid hypothesis does not explain how the PSEN1 mutant 
phenotypes with commonly observed lower steady-state levels of A42 could still lead to more 
pathogenic oligomers. In this author's view it would require that i) physiological oligomers are hetero-
oligomers consisting of mixtures of A42 and A40; such hetero-oligomers have been studied by 
Pauwels et al.[165]; ii) local surplus of A42 seeds A42-enriched hetero-oligomers that may be more 
pathogenic and plausibly more resistant to degradation than oligomers of lower A42 content, so that 
the clearance is reduced to increase the steady-state pool of pathogenic oligomers. This competitive 
seeding mechanism could explain why a larger A42/A40 ratio, but not the total A42 levels, may cause 
disease. 
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 Second, it is a shortcoming of the amyloid hypothesis that the normal functions of A and APP 
and, for that matter the other APP products, sAPPα and AICD[120], are not accounted for: APP-related 
proteins are merely viewed as pathogenic, yet the elaborate splicing of APP is clearly there for a reason, 
and there is substantial support for a physiological role of A[166][167][168][169]. In addition, AICD 
regulates transcription in a way that somewhat resembles that of the intracellular domain of Notch also 
produced by γ-secretase[170]. These functions of cleavage products further complicate the strict 
amyloid gain-of-function hypothesis[47]. Specifically for A, concentrations below nano-molar (as 
encountered within cells) are neurotrophic whereas only high concentrations (typically micro-molar 
levels as seen in cell assays) are toxic[168][171]. This suggests that there is a therapeutic window of Aβ 
levels that should be stabilized, rather than merely reduced.  
 Third, current research models of the amyloid hypothesis rely on measurements of Aβ 
toxicities[172] and aggregation tendencies[173] occurring at micro-molar concentrations, 
corresponding to ~1 year of total brain production, 1000-fold higher than the biologically relevant 
concentrations[174][175]; yet AD is age-dependent and gradually develops over years. Some toxic 
modes associated with physiologically relevant concentrations have been reported[126][176], but the 
toxic mechanism of A oligomers remains debated[130][177].  
 The amyloid hypothesis lends support from APP mutations that cause AD, and specific Aβ 
variations are widely heralded as confirming the amyloid hypothesis, a notable example being the 
recently identified protective A2T variant[178]. Figure 4 shows the sites of Aβ mutation and cleavage 
in APP. Attempts to link clinical phenotypes (protective vs. pathogenic) to actual biochemical 
properties are being made, with particular focus on the effect on APP cleavage, and thus Aβ production, 
and aggregation tendencies[179]. However, data from APP mutant models are mixed[180][181][182]: 
Some cases show normal behavior despite high amyloid levels[183], while impairments resembling AD 
features can be induced by other features such as metabolic deficiencies[184].  
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Figure 4. The Aβ region of APP. Cleavage by α-, β-, and γ-secretases is shown in green, and disease-
related mutations are shown in red. 
 
 Furthermore, meta-analysis shows that reported biochemical data for Aβ variants are 
disturbingly heterogeneous: Published amyloid levels and A42/A40 ratios measured in cultured cells, 
toxicities from cell viability studies, and aggregation propensities from thioflavin T assays for these 
variants scatter to the extent that conclusions based on any one or even several of these variants are 
statistically meaningless and thus do not support the "quantitative" amyloid hypothesis[9]. Distinct 
toxicities of Aβ variants expressed in cell lines do correlate with their aggregation tendencies in cell 
assays[118][124]. Yet, while the relationship between cell toxicity and aggregation propensity is 
strong[118], these toxicity and aggregation data do not correlate to human clinical data of Aβ variant 
carriers at all[9]. Thus, at best, data from cell and mouse models are too heterogeneous to give insight 
into human disease, at worst, they are fundamentally unrelated to the disease[9]. 
 Fourth, the APP mutations are even more problematic than the biochemical heterogeneity would 
imply: Different mutations in APP produce distinct histopathologies and different intensities of tangles 
and plaques as typified by cerebral amyloid angiopathy (CAA) vs. classical AD; some variants lead to 
increased, others to decreased total Aβ levels; variants such as A2V, H6R, D7N (using the Aβ 
numbering scheme) produce Aβ42/Aβ40 ratios similar to wild type APP, whereas APP variants E22G, 
E22K, and E22Q lower this ratio; and average clinical ages of symptom onset vary from the thirties to 
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the sixties of age[9]. In conclusion, the biochemistry of APP mutations provides no evidence of gain of 
function and does not explain variations in clinical outcome.  
 A fifth point of concern is that while it is thus increasingly clear from correlation studies that 
the Aβ variants tell us little about disease[9], the PSEN1 variants tell us a lot[156]. Many more 
mutations in PSEN1 than in APP cause AD, although APP contains the final A product[59], and the 
PSEN1 mutations have chemical properties that have now been directly correlated to clinical FAD 
characteristics[156]. These PSEN1 mutations cause lower γ-secretase activity and reduced production 
of A; this could suggest that PSEN1 is more central to AD than Aβ is[185]. The PSEN1 mutant 
phenotypes are much more clinically and biochemically homogenous than are the APP phenotypes, as 
they produce classical AD phenotypes and tend to increase Aβ42/Aβ40 ratios in most cases[186]. The 
Aβ42/Aβ40 ratios correlate with actual human clinical data[156]. Thus, a competitive seeding mechanism 
that would lead to gain of toxic oligomers could be a determinant of human AD as cell and mouse 
models do not capture such a mechanism. Yet, it could equally reflect loss of functional monomeric Aβ, 
to be explored below. 
 Sixth, the other important histopathological features of AD, e.g. metabolic deficiencies, massive 
post-translational modifications, metal ion imbalances, and oxidative stress, are not accounted for in 
any current version of the amyloid hypothesis [19]. It is unsatisfactory that the amyloid hypothesis does 
not explain the main risk factor of disease (age) as emphasized by e.g. the two-hit hypothesis[187]. The 
aging human proteome is the relevant framework for understanding AD. The aging proteome exhibits 
down-regulation of genes involved in synaptic function, including calcium homeostasis and signaling, 
and vesicular transport, and upregulation of anti-stress and anti-inflammation genes[38]. The amyloid 
hypothesis, founded very much on the FAD mutations in PSEN1 and APP, does not explain the vast 
majority of sporadic AD cases, where no such Aβ-related genes seem to be strongly involved. 
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 Finally and most importantly, the amyloid gain-of-function hypothesis has so far failed utterly 
in its attempts to produce a cure or even halt of AD[7][11]. The clinical human data have not confirmed 
the supposedly promising data from cell and mouse models used to research the drug candidates of the 
main pipelines[13][163], consistent with the poor correlations between human clinical data and these 
types of data models that is already clear from meta-analysis[9]. In fact, clinical trials essentially 
disprove the quantitative gain-of-function hypothesis[6][12][188][189], but perhaps not a qualitative 
gain-of-function mechanism centering on specific local pools of Aβ42-enriched hetero-oligomers. The 
following should be noted: 
 (i) Active Aβ immunization with AN1792 produced cases of brain inflammation and continued 
cognitive decline[190], and no such treatment strategy has produced favorable Phase 3 outcomes[180];  
 (ii) Passive Aβ immunization with Solanezumab showed no improvement in cognitive function 
in the two major phase 3 trials[191]; however subsequent analysis of the combined data revealed a 
positive effect on cognition[192][193]. Also, Bapineuzumab did not show any benefits[194] and can 
produce adverse effects vs. placebo[195] despite lowering amyloid levels[196]. Gantenerumab is 
currently being continued despite reports of inflammation[197]. Since the antibodies bind differently to 
Aβ, they may affect the functional monomer pool and the oligomer pools differently, and in principle, 
this may be a useful way to reconstitute functional loss of Aβ monomers. 
 (iii) Both the γ-secretase inhibitors Avagacestat and Semagacestat that reduce Aβ production 
have shown adverse cognitive side effects, and were discontinued[198][199]. While this has been 
interpreted as possibly due to impairment of Notch signaling and other adverse effects of reduced 
PSEN proficiency, the immunization data are more consistent with loss of Aβ function in the light that 
a therapeutic window of neurotrophic Aβ levels are well-established[168][171] and since these 
strategies do not impair other functions of PSEN1. Instead, both adverse clinical outcomes of passive 
immunization and γ-secretase inhibition can be explained by loss of function.  
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 The gain vs. loss of function hypotheses are summarized in relation to some central data in 
Table 1. The possibility of a loss of function mechanism will be explored in detail in the remainder of 
this review. 
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 Table 1. Observations related to AD can be explained both as gain or loss of Aβ functiona. 
Observation Explanation, gain of function Explanation, loss of function 
Aggregation  oligomers are toxic by some 
specific mechanism 
oligomers represent loss of 
functional monomer 
PSEN1 mutant phenotypes high Aβ42/Aβ40 ratios increase 
Aβ oligomer pool or specific 
toxicity, even if total Aβ42 levels 
decrease 
less produced Aβ represents loss 
of function; however, increased 
oligomerization reduces 
functional monomer pool  
APP mutant phenotypes mixed phenotypes cannot be 
consistently explained. Some 
affect APP cleavage to increase, 
others to reduce Aβ levels 
N-terminal mutants lose metal-
binding; C-terminal and over-
expressing mutants aggregate and 
lose monomer pool 
Toxicity upon overexpression 
of FAD mutants 
oligomers are toxic by some 
specific mechanism 
depletion of metal status in cells 
adverse effects of γ-secretase 
inhibitors 
due to lack of selectivity and 
Notch impairment 
due to reduced functional Aβ 
levels, as in PSEN1 phenotypes 
adverse effects of passive Aβ 
immunization 
not targeting the right form of 
Aβ 
due to reduced functional Aβ 
levels 
Positive effects of some Aβ 
antibodies 
removing pathogenic oligomers reconstituting functional 
monomers 
Oxidative stress and metal 
dyshomeostasis 
possible toxic modes of Aβ-
metal interactions 
directly related to APP/Aβ 
function (loss of Aβ function 
causes copper buildup in cells) 
a See text for discussions and specific references. 
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Moving forward: What does the structural chemistry of Aβ peptides tells us? 
While the heterogeneity in clinical data is due to disease risk modifiers, the substantial heterogeneity in 
biochemical data for Aβ variants, such as measured aggregation tendencies from thioflavin T assays, is 
due to different lab protocols and the special chemical features of Aβ[9]. Efforts are ongoing to 
produce consistent, stable, and reproducible monomeric and oligomeric Aβ samples that will remove 
some of the protocol-based heterogeneity[200][201][202]. However, even beyond the sample 
management issue, the structural variability of these highly disordered peptides[203] renders observed 
properties such as toxicity very conformation-dependent, and, since conformation is very dependent on 
chemical environment, Aβ structures and their derived toxicities are highly sensitive to concentration, 
pH, ionic strength, co-solvents, and the time scale of the experiment performed[118][204].  
 Identifying the physiologically relevant structures of the Aβ monomer is a necessary 
prerequisite to understanding both its oligomerization and potential gain of pathogenic action, but also 
its natural roles[9][20][123][205] such as membrane interaction[206][207]. In water, the free Aβ 
monomer has a disordered coil-dominated structural ensemble with some helix and little β-
strand[203][208][209][210]; this is consistent with available nuclear magnetic resonance (NMR) and 
circular dichroism (CD) spectroscopic data on the monomer and reflected structural models with PDB 
codes 1BA4[211], 1IYT[208], 2LFM[143], 1Z0Q[209], and 1AML[212].  
 In co-solvents and close to membranes, the helix content of Aβ monomers increases[212], due 
to the helix dipoles being stabilized in low-dielectric environments[213]. The shape-shifting nature is 
illustrated by two representative structures deduced from NMR data in Figure 5A, showing the Aβ 
structure in water, and Figure 5B showing the structure of Aβ in a membrane-mimicking chemical 
environment; in the latter case, the C-terminal of Aβ has become an extended, potentially membrane-
spanning helix, an observation that fits well with the widely documented membrane channel properties 
of Aβ[134][136][214]. 
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Figure 5. The shape-shifting nature of Aβ: A) NMR-derived structure of Aβ40 in water (PDB: 
2LFM)[143]. B) NMR-derived structure of Aβ40 in a micelle membrane-mimicking environment (PDB: 
1BA4)[211]. The hydrophilic N-terminal is shown on top, whereas the hydrophobic C-terminal, which 
forms helix in the membrane-environment, is shown to the lower right in both cases. 
 
 
 On the other hand, if the monomer Aβ is subject to other chemical interactions or modifications, 
such as high Aβ concentration, contact with metal ions[215][216][217][218][219] or genetic 
mutation[220][221], it forms oligomers and fibrillar aggregates. In these structures, the peptide 
converts structure from helix-coil to the extended sheets of β-strands found in senile plaques, as seen in 
Figure 2B[209]. As an example of the relevance of time scale, Abelein et al.[222] found mainly coil, 
some indications of helix, and no β-strand in the pure Aβ40 monomer, but after days at room 
temperature they observed β-strand characteristic of aggregated peptide[222]; the fibrils making up the 
senile plaques consist mainly of such extended sheets, packed with metal ions[209][223][224].  
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 Considering the major structural variability of Aβ occurring both in vitro and in vivo, attempts 
have been made to identify the "physiologically relevant" ensembles of the peptide, by correlating 
specific structures directly to human clinical outcome and cell toxicities. This provided the first 
statistically significant relationships between fundamental chemical properties and clinical and 
biochemical phenotypes[118][124][213]: Remarkably, hydrophobic exposure in the most disordered 
structures of Aβ correlate with features of the human disease, i.e. the diagnosis age of patients carrying 
a specific variant, whereas other structures do not. This could suggest that the coiled disordered 
structures with a small (<25%) helix segment are the physiologically relevant forms of Aβ[213].  
 The differences in experimental toxicities of genetic Aβ variants are well explained by each 
variant's conformational ensemble: Specifically, toxicity correlates with the extend of hydrophobic 
exposure of disordered structural parts of the variants, providing a detailed molecular picture with 
statistically significant correlations to experimental toxicity data[118][124]. Thus, Aβ aggregation and 
cell toxicity is caused by hydrophobic exposure in specific disordered amyloid states that can be 
targeted by molecular intervention, e.g. antibodies[158][160]. However, in the light of the poor 
correlation between toxicity assays and clinical disease features[9], the question still remains whether 
this oligomerization-driven cell toxicity has anything to do with AD. 
 
Evidence for normal physiological functions of APP/A 
Mouse knock-out experiments indicate that APP-related proteins have physiological roles: APP-
knockout alone reduces synaptic proliferation, whereas single-knockout of the related amyloid 
precursor-like protein 2 (APLP2) does not affect neuron function and morphology[225]. However, 
knockout of both APP and APLP2 simultaneously is lethal and indicates an important role of 
APP/APLP2[226][227] and that each protein can compensate the absence of the other[228]. Although 
these proteins are unimportant for cell differentiation[229], they affect synaptic plasticity under normal 
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conditions[230] and are essential for hippocampus function and spatial learning of mice[231]. The role 
of APP or its cleavage products is also seen from its importance in resisting kainite-induced 
seizures[232]. The APP family of proteins are mainly important in aged, not juvenile mice[227]. 
Consistent with these experiments, several roles of these proteins in maintaining synapses have been 
identified[233][234]. 
Aβ produced from APP also has a normal function in cells: The work by Yankner et al.[171] is 
often cited by proponents of the gain-of-function amyloid hypothesis as evidence of toxicity. However 
the work actually found beneficial effects of the peptide at lower concentrations, but toxic effects at 
higher concentrations[171]. Plant et al. have confirmed this by different lines of investigation, showing 
that inhibition or depletion of A40 by either secretase inhibitors or A antibodies is lethal to cultured 
neurons, and A40 is protective in a concentration-dependent way, whereas A42 was not[235]. Aβ 
depletion also impairs neuronal activity in mice[166]. Important hints to the nature of this function 
comes from work showing that Aβ monomers protect against copper- and iron-induced toxicity[167] 
and play a natural role in regulation of vesicle release in hippocampal synapses, with more extracellular 
Aβ related to increased release probability[169].  
These various findings indicate that loss-of-function is a real peril that must be accounted for, 
and the studies therefore anticipated the negative outcome of strict -secretase inhibitors such as 
Solanezumab ten years later[198]. At that time, the impaired proficiency and reduced Aβ levels of 
FAD-causing PSEN1 mutations were also well known, further mystifying the rationale behind the 
quest for strict Aβ containment. This is a remarkable example of the inability of scientific paradigms to 
rationally self-correct, but it also reflects negatively on the R&D management of major companies who 
were obsessed with the toxic side of the therapeutic Aβ window while ignoring the neurotrophic side; 
this has, unfortunately led to a waste of research (and shareholder) funds, and more importantly, to a 
delay in the testing of drug candidates that could be truly efficient[163][236]. And still today, research 
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and drug development efforts do not present a balancing strategy of Aβ, despite evidence summarized 
above that such a balance is necessary.  
 
Figure 6. Zinc sites (zinc shown in yellow) in key proteins relating to Alzheimer's disease: A) Aβ 
based on the NMR structure 1Z09.pdb[237]; B) the crystal structure of the E2 domain of APP 
(3UMI.pdb)[238]; C) ADAM17 as a representative of the ADAM family of zinc peptidases with α-
secretase activity, based on the structure 3LE9.pdb[239]; D) Loss of metalloprotein function 
contributes substantially to the pathology of Alzheimer's Disease. Insulin degrading enzyme is one of 
several Aβ-degrading zinc peptidases that will lose function upon metal dyshomeostasis (figure made 
from coordinates in the reported crystal structure 2WK3.pdb[240].  
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The natural function of APP: Metal binding and transport  
In the following, it is argued that the normal physiological function of APP/Aβ is regulation of intra-
neuronal relative copper levels via low-to-moderate affinity divalent metal transport. The theory that 
metal ion imbalances play a role in AD is well-established[19][34][46], and in particular calcium has 
been associated with AD for three decades[241] and reviewed in detail[28][29][135][137][242][243]. 
Most of the proteins central to AD have copper or zinc sites, with some examples shown in Figure 
6[19][244]. Evidence for APP as a metal transport protein includes the following: 
i) First, APP has multiple established metal binding sites[245][246][247][248]. The large 
extracellular part of APP is generally divided into two domains, E1 and E2 : E1 consists of the growth-
factor like domain that contains a heparin binding loop [247] and the copper-binding domain 
(CuBD)[249][250] consisting of His151, His147, and Tyr168[249][251]. The affinity for copper is 
moderate, approximately 10 nM[246]. There is also a Zn(II) site within residues 181−200[252]. Several 
Cu(II) and Zn(II) sites are present in the E2 domain of APP-like proteins reported to regulate 
conformation and possibly function[238][253].  
ii) APP reduces bound Cu(II) to Cu(I) in association with electron transfer and disulfide bond 
formation[254]. The combination of copper binding sites and this redox chemistry has been suggested 
to imply that APP transports Cu(I) across the membrane in analogy to other copper-transporting 
proteins having membrane-associated copper binding sites that reduce Cu(II) to the transportable Cu(I) 
oxidation state, e.g. the plasma membrane copper transporter Ctr1, which is cleaved from the 
membrane upon high copper status to prevent uptake of copper[255].  
iii) Knockout of APP in cultured neurons leads to reduced Cu(I) induced toxicity in 
neurons[256], suggesting that APP is essential for neuronal copper uptake. In addition, overexpression 
of APP leads to intracellular copper deficiency and overexpression of the Aβ-containing C-terminal 
fragment of APP leads to both copper and iron deficiency in mouse brains[257]. Copper efflux function 
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due to APP can be reduced by copper chelating ligands[258]. The specific copper-binding domain of 
APP has been shown to reduce toxicity from copper exposure[259]. 
iv) Other researchers have found[260] that increased copper exposure in aged mice leads to Aβ 
accumulation and down-regulation of low-density lipoprotein receptor-related protein 1 (LRP1) – a 
transporter of Aβ [261] that also controls APP trafficking and processing[262][263].  
 v) Buxbaum et al. found 20 years ago that APP cleavage is regulated by increases in either 
protein kinase C or calcium levels independently[264]. Secreted forms of APP have been found to 
protect against excitotoxicity and reduce calcium levels in cells[265]. Addition of the 105-residue C-
terminal fragment of APP to cultured cells has been found to increase intracellular calcium levels and 
make rat cortical neurons more prone to glutamate-based excitotoxicity; calcium levels could, 
interestingly, be reduced by cholesterol[266]. The C-terminal fragment is neurotoxic both with and 
without the Aβ sequence fragment included[267].  
 vi) APP stabilizes the Fe(II) exporter ferroportin and has been suggested to be analog of 
ceruloplasmin (a copper- and iron transport protein that interacts with ferroportin) although it does not 
have ferroxidase activity as initially suggested [268]. 
 
Aβ: A metal ion transport peptide 
If APP is a membrane protein that controls certain aspects of intra-neuronal metal status, the question 
is, how does it do so? One answer to this question is by its intrinsic ability to bind and respond to metal 
ions within the membrane, as summarized above; the other is by the use of its splicing product, the Aβ 
peptide. The evidence for such a mechanism is now presented: 
i) First of all, A is itself a genuine metal-binding peptide with an archetypical N-terminal 
metal-binding site constituted by three histidines (His-6, His-13, and His-14 using Aβ numbering, see 
Figure 4)[269][270]. Metal ions such as Cu(II) and Zn(II) mostly form 1:1 complexes with A, 
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sometimes with a secondary, low-affinity binding site[248][271][272][273]. The binding of metal ions 
to A changes its structure and induces formation of fibrils[272][274]; these metal-rich fibrils resemble 
the senile plaques characteristic of AD.  
ii) Furthermore, A is also an archetypical amphiphile: It has a hydrophilic N-terminal region 
with established metal binding properties and a hydrophobic C-terminal region providing its membrane 
affinity[19]. This amphiphilic design seems ideal for micelle- or membrane-channel formation.  
iii) As the apo-A carries a charge of −3, binding of metal ions of positive charge +2 or +3 
would increase A hydrophobicity and most likely also its association with membranes[213].  
iv) The Aβ monomer is disordered in aqueous solution but forms helix structures in low-
dielectric environments such as co-solvents and micelles, thus providing a structural rationale for its 
membrane channel function[135][214][275][276], not simply as a toxic mode of Aβ action but as a 
potential natural function of the peptide.  
In summary, the “shape-shifting” nature of Aβ, the increased helix forming tendency in 
membrane environments, its metal-binding properties, and the amphiphilic chemical features 
(hydrophilic N-terminal half, hydrophobic C-terminal half) indicate that the peptide has evolved to 
interact with metal ions and cell membranes as part of its natural function.  
Indeed, such a function has been observed: Aβ forms channels that enable calcium transport 
through membranes[135][136][277][278][279], and these channels can be blocked by zinc[207][214]. 
Also, the loss of cellular copper causes copper depletion in the highly abundant cytosolic anti-oxidant 
protein SOD1 that plays a central role in amyotrophic lateral sclerosis (ALS) which shares many 
similarities with AD[19][280][281]; dietary copper compensates this loss and reduces Aβ 
production[282].  
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Regulation of the APP/Aβ metal transport system: Enter secretases 
As evident from the research summarized above, APP and Aβ are genuine metal proteins and metal 
peptides, respectively, having strong association with membranes and direct effects on intra-neuronal 
metal status. However, the mechanism by which such an APP/Aβ system senses and regulates metal 
status remains to be explained. I argue here that this regulation mechanism works via the much studied 
(in the different context of amyloid production within the amyloid hypothesis) splicing of APP by the 
α-, β-, and γ-secretases.  
 i) First, β-site APP cleaving enzyme 1 (BACE1), the aspartyl protease that initiates production 
of Aβ by cleaving its N-terminal from APP[283], contains a copper site, and overexpression of BACE 
leads to reduced SOD1 activity consistent with loss of intracellular copper (copper availability is 
required for proper holo-protein SOD1 folding and activity)[284][285]. This suggests that BACE 
activity somehow reduces copper status in neurons. Hou et al. showed that not only does copper 
exposure lead to increased APP expression and Aβ formation, it does so by action of a copper sensing 
protein (CUTA) that directly interacts with the β-cleavage site of APP[286], and recently, Multhaup's 
group showed that the transmembrane region of BACE1 contains a genuine, highly conserved cysteine-
and methionine-rich copper binding site, which loses copper binding affinity upon mutation of cysteine 
to alanine[287]. Supplementing this evidence, Gough et al. showed that N-terminal archetypical metal-
binding site of Aβ, which is also the β-cleavage site, constitutes the actual site that regulates β-secretase 
cleavage of APP[288]. These various data strongly suggest that BACE1 is activated by copper levels 
by specific copper binding to facilitate cleavage of APP. 
 ii) A variety of metal chelators reduce amyloid plaque formation[289], down-regulate APP 
expression and lower Aβ secretion as a response to the depletion of the intracellular free copper 
pool[290]. Strong metal chelators such as EDTA reduce γ-secretase activity and thereby, production of 
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Aβ, consistent with a reduction of intra-neuronal metal status directly down-regulating Aβ-producing γ-
secretase activity[291]. Zou et al. found that the beneficial effect of monomeric Aβ in protecting 
against metal-induced oxidative stress toxicity resembles that of classical non-natural metal chelators 
such as EDTA[167]. 
 iii) Inhibition of copper transporters increase Aβ in brain lysates and decrease expression of Aβ-
degrading proteases [292].  
 iv) Copper-induced toxicity in rabbits leads to learning impairment and to enhanced Aβ plaque 
formation, suggesting that production of Aβ from APP increases with metal status[293].  
 A consistent explanation of these observations is that high copper status is counteracted by 
activation of the amyloid-producing secretases, leading to cleavage of APP and production of the 
copper-transport peptide Aβ, which is then exported out of neurons to produce the metal-enriched 
plaques that characteristically define AD in human brains. Thus, APP/Aβ is probably a neuronal metal 
transport system, with the spliced Aβ peptide working as an exporter in combination with the low-
density lipoprotein receptor family of proteins. The widely studied cleavage of APP by α-, β-, and γ-
secretases to produce Aβ is therefore suggested to be a regulation mechanism of neuronal metal status. 
It is notable that by analogy, the plasma membrane copper transporter Ctr1 is also cleaved from cell 
membranes: Its cleavage is a result of high copper load, to prevent copper uptake[255].  
Observing the chemical composition of senile plaques, with their massive co-location of copper, 
zinc, and iron ions[209][223][224], they might be referred to as amyloid-metal deposits rather than 
simply amyloid deposits. These plaques are non-pathogenic[107][108], and the aggregation propensity 
of amyloid variants does not correlate with disease severity[9]. Why then do we see this buildup of 
plaques if not as part of the pathogenesis itself? The alternative answer is: Either as an irrelevant 
downstream consequence of the true pathogenesis, or due to a protective mechanism related to disease. 
Within the view presented here, these metal-enriched plaques are a natural result of excessive metal 
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export from the neurons via Aβ, a metal-binding amphiphilic membrane-associated peptide plausibly 
evolved specifically for this purpose.  
Accordingly, the ability of metal ions to bind and induce Aβ aggregation[19] 
[46][217][218][219][294], which has so far been interpreted as a toxic mechanism of metal-Aβ 
interaction, can instead be explained as a physiological metal-Aβ interaction and metal-export-deposit 
function. The observations of beneficial effects of metal chelators on A status in cultured 
cells[295][296] and in Drosophila that expresses human Aβ[297], and on the cognition of mice[298] as 
a result of the reduced intracellular copper levels and concomitant reduced Aβ production, are all in 
line with the regulation mechanism suggested above.  
 
Aggregation causes loss of functional Aβ monomer  
It may seem ironic to a community accustomed to the gain-of-toxic-function amyloid hypothesis to 
think of the opposite scenario, loss of normal Aβ function. However, the main observations in support 
of gain of function are equally consistent with loss of function, whereas various other observations are 
mainly consistent with loss of function. 
 First of all, accounting for the normal beneficial functions of Aβ40[166][167] should be 
expected even of a gain-of-function mechanism, yet the gain-of-function hypothesis does not do so, 
despite the established normal functions. Gain of function is usually attributed to the PSEN1 and APP 
genetic mutations because they are mostly autosomal dominant[299][300]. The gain of function is 
supposed to arise from an increase in quantity or malicious quality of Aβ oligomers by means of 
aggregation processes, consistent with mostly autosomal dominant mutations[117][133]. As the total 
Aβ pool consists of innocent, functional monomers and pathogenic non-functional oligomers, 
oligomerization implies a depletion of the pool of functional Aβ monomers concomitant with an 
increasing oligomer pool. The dominant FAD mutations can therefore equally well cause disease by 
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loss of Aβ function, since the heterozygote's wild type Aβ cannot protect itself against aggregation and 
thus, depletion of the overall pool of Aβ monomers. 
 Loss of Aβ monomers is consistent with the fact that total Aβ levels decrease in most FAD-
causing mutants[146][185], whereas gain of function requires a specific mechanism driven by 
increased local Aβ42/Aβ40 ratios, as discussed above (competitive seeding). Most of the genetic risk 
factors of FAD are now known to reduce soluble monomer Aβ40 levels either directly[185] or by 
increased aggregation: A40 production is in some cases halved by PSEN1 mutations [301], and if the 
A42/A40 ratio causes aggregation, this would equally constitute a substantial loss of the normal 
functions of Aβ[302]. Typical A deposits in senile plaques correspond to perhaps 5−10 years of total 
A production, or about seven years calculated recently[105]. Rather than implying, as commonly 
done, that these plaques represent a toxic overload of Aβ, clearly, the documented functions of Aβ will 
be affected by such a massive deposition.  
 
Metal homeostasis and AD 
Dyshomeostasis of calcium, zinc, iron, and copper levels is an established pathological feature of 
AD[19][31][34][46][216][243][303], as probably first suggested in the case of zinc by Burnet[304]. 
The massive metal-enrichment in senile plaques[46][270][305] was a hint of this, but it is more 
specifically seen from upregulation of metal transport proteins in APP/PSEN1 mutant expressing 
mice[306][307] and upregulation of zinc transporters[306][308] and metallothioneins[309] in AD 
patients. The heterogeneous data on metal status in AD brain parts can be reconciled by a mechanism 
whereby metal ion status is perturbed from the bound pool in proteins to the free pool in the cytoplasm; 
this shift has many biochemical consequences[19].  
 While metal imbalances could be a consequence of general neurodegeneration and thus not 
causative, there is support for a causal role[19][46]: One example is the "zinc cascade", zinc's control 
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over the Aβ balance via zinc peptidases involved both in Aβ formation and degradation[19]. Cleavage 
of APP at the -cleavage site, which lies within the A region and thus prevents amyloid production, is 
catalyzed by membrane zinc-proteases of the ADAM family (A Disintegrin And Metalloprotease 
family)[310][162] (Figure 4C). A is rapidly degraded by a number of proteases[311], notably 
neprilysin[312][313], angiotensin-converting enzyme[314], matrix metalloproteases[315][316][317], 
and insulin degrading enzyme[318][319] (Figure 4D). As previously pointed out[19], all of these are, 
curiously, zinc proteases. Impairment of some of these proteases can be related to AD[317]. If zinc 
dyshomeostasis manifests as loss of functional protein-bound zinc pools, these zinc enzymes would be 
impaired, providing a direct causal relationship between zinc homeostasis and amyloid balance[19].  
 The homeostasis of the three divalent metal ions calcium, copper, and zinc is tightly controlled 
due to the narrow window between nutritional value in important proteins and toxic nature in free 
form[320]. Dependent on their mutual concentrations, they serve in neuron signaling, apoptosis, 
inflammation, oxidative stress control, and cell proliferation: In particular, life-death processes of cells 
are controlled by calcium[321][322][323] and zinc levels[324][325][326], and zinc plays a central role 
in the apoptosis, oxidative stress, immune defense, neurogenesis, and synaptic plasticity[327][328]. 
Calcium-regulated life-death choices work through transcription factors such as MEF2[322], which are 
also risk factors of AD recently identified from GWAS[73].  
 Their homeostasis is intimately linked and synergistic[329]: The zinc-regulated life-death 
choices are regulated by oxidative stress and are coupled to copper levels and metallothioneins[330].  
Increased cytoplasmic zinc levels elevate calcium levels and activate calcium-dependent signaling 
pathways that lead to death[331]. Notably, zinc also inhibits Notch signaling[332], which modulates 
cellular life-death decisions via zinc finger transcription factors, and this mechanism provides one of 
several pathways that unify SAD and FAD, with PSEN1 phenotypes having genetically impaired Notch 
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signaling due to PSEN1 mutation, where zinc overload provides a sporadic counterpart of impaired 
Notch signaling. 
 The metal ions need to be treated differently and are heterogeneously distributed in the 
brain[333]: Copper is redox-active and binds more strongly to the nitrogen donor ligands of APP and 
Aβ, which can be explained from the Irving-Williams series of chemical binding constants[19]. Copper 
is particularly enriched in the hippocampus where AD typically starts[334]. In contrast, calcium and 
zinc are redox-inactive but calcium is oxophilic and preferably binds to oxygen-donor ligands, whereas 
zinc also binds nitrogen- and sulfur-donor ligands; they also differ in terms of cellular distribution and 
abundance: Calcium is most abundant, whereas zinc is abundant in vesicles of zinc-enriched neurons, 
transported by ZnT3 transporter proteins[335][336], and zinc is deposited in AD patients together with 
plaques, around impaired blood vessels, and in cells with tau pathology[337], with significantly 
increased levels in hippocampus of AD patients[338]. 
 Copper is used in active sites of enzymes such as cytochrome c oxidase of the mitochondrial 
respiratory chain and SOD1[19]. Loss of functional copper would lead to impairment of the respiratory 
electron chain and mitochondrial energy inefficiency, increased oxidative stress and potentially 
apoptosis of the neuron; thus metal dyshomeostasis can cause mitochondrial dysfunction characteristic 
of neurodegenerative diseases[19]. SOD1 is located on chromosome 21 like APP and plays a key role 
in zinc/copper homeostasis and oxidative stress control in the vulnerable neurons with their high 
oxidative metabolism[339]. Mutations in SOD1 is a major genetic risk factor of familiar 
ALS[340][341]. Another gene on chromosome 21, Down syndrome critical region gene 1, produces 
cognitive deficits and inhibits Calcineurin's calcium-dependent phosphatase function[342], which 
contributes to the neurological impairment characteristic of trisomy 21. Copper dyshomeostasis is well 
known to be neuropathological as evident from e.g. Menkes and Wilson's diseases[343][344].  
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Based on the available evidence summarized so far, it can be suggested that APP/Aβ controls 
secondary metal level balances, notably the Cu/Zn ratios, and, in combination with presenilins, the 
Cu/Ca ratio. This is consistent with the moderate affinity of the metal sites in APP[246] and Aβ[19]; 
metal transporters generally separate into high- and low-affinity types based on their role, and low-to-
moderate affinity seems suitable for ratio maintenance, whereas high-affinity transporters control 
primary import and export[345]. The APP/Aβ is thus most likely a secondary metal transport system 
with metal ion selectivity: For example, copper is known to bind 2−3 orders of magnitude more 
strongly to Aβ than zinc[19]. This implies that the main function of APP/Aβ is to balance relative intra-
neuronal metal levels.  
The proposed function of APP/Aβ and its loss-of-function role in AD is supported by the 
findings that presenilins induce copper and zinc uptake[346], while they leak calcium[347][348]. This 
indicates that presenilins are involved in maintaining Cu/Ca and Zn/Ca ratios. APP’s established 
dimerization equilibrium and its proteolytic processing[349] may thus be a mechanism to control 
Cu/Zn and Cu/Ca levels in neurons; this dimerization of APP and associated Aβ production is 
facilitated by copper levels[350]. The processing of APP by presenilin-containing γ-secretase has 
recently been suggesting to be directly coupled to channel formation in presenilin, so that APP 
cleavage and channel activity may be linked[155].  
As discussed above, there is evidence that metal binding at the archetypical N-terminal Aβ site 
within intact membrane-bound APP triggers APP cleavage and production of Aβ. Possibly, although 
speculative, the formed metal-Aβ peptides then use the instantaneously formed pores in presenilin to 
immediately exit the membrane after they have been produced by APP cleavage. This mechanism 
would explain why A cation-selective channels are inhibited by zinc[206][207][214], an unusual 
property if not enabled to ensure metal ion selectivity of the APP/Aβ system. This "made-to-go" 
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mechanism would provide a pathway for extracellular deposition of metal-enriched senile plaques and 
explains why zinc exposure increases Aβ production from APP and leads to Aβ deposits[351].  
 
CAA vs. AD: An explanation based on normal Aβ function  
An important piece in the puzzle is the observation that genetic Aβ variations (see Figure 4) located 
within the N-terminal 1−16 region tend to give rise to classical AD phenotypes, whereas mutations 
within the C-terminal part of Aβ beyond position 20 cause CAA, e.g. the Dutch, Italian, Flemish, 
Arctic, and Iowa variants[9]. Also, all the FAD-related APP mutations that increase total amyloid 
levels are located in the N-terminal half of the peptide[9]. No one has provided an explanation for these 
differences. The common argument from the amyloid gain-of-function paradigm is that these mutants 
affect α-, β-, and γ-cleavage of APP in different ways: Clearly, the mutants are located in the 
neighborhood of these APP cleavage sites, and the Swedish double-mutation at the β-site (but outside 
the Aβ sequence) supports this view as it leads to large quantities of Aβ[352]. Others emphasize the 
changes in aggregation behavior of the produced Aβ variants themselves, as e.g. the highly 
aggregation-prone Arctic E22G variant[353][354].  
 As explained above, neither of these two features can explain the pathogenicity of APP 
variations: The Aβ42/Aβ40 ratio increases significantly vs. wild type in only two variants, D7H and 
E11K[9]. Total Aβ levels increase in A2V, D7H, E11K, K16N, and A21G, all in the N-terminal half. 
The assumed protective A2T variant reduces Aβ levels possibly by modifying the β-cleavage site[355], 
as the Swedish mutant. However, the pathogenic Osaka E22∆ variant also reduces Aβ levels, and the 
English H6R, Tottori D7N, Arctic E22G, Italian E22K, and Dutch E22Q do not change Aβ levels 
significantly[9]. If overproduction of Aβ (despite unaltered ratios) by A2V and the Swedish mutation 
should cause AD, it would be by a mechanism distinct from most APP and PSEN1 mutations. Yet, 
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researchers curiously continue to discuss models of AD, such as the Swedish model discussed below, 
as if overexpression of Aβ due to altered APP cleavage is a central feature of the disease. 
 If altered APP cleavage cannot explain the FAD/CAA mutants of APP, then, if we rely on the 
amyloid hypothesis, the changed product has to be pathogenic in those other cases where Aβ itself is 
changed without affecting β-cleavage, i.e. instead of levels (quantitative gain of function) it must be 
properties (qualitative gain of function). As discussed previously, there is no indication that the 
aggregation propensities, as presumably related to disease within the gain-of-function paradigm, has 
anything to do with disease: Many variants do have higher aggregation propensity than the wild type 
Aβ, which is rationalized by their tendency to increase hydrophobic exposure or reduced 
hydrophilicity[118]. However, there is no positive relationship between disease severity and 
aggregation tendency, in fact perhaps even the opposite: The four clinically most severe variants, A21G 
and A2V, E22Q, and E22∆ (age of symptom onset from 36−52 years) have smaller tendencies to 
aggregate than some other variants such as the English and Tottori variants with 56−61 years of 
onset[9], i.e. aggregation is not pathogenic and perhaps even protective. 
Instead, the increased amyloid production seen in cultured mutant cell models resulting from 
mutation in the N-terminal of Aβ can be explained as a changes in metal-binding properties, with 
metal-binding ligand residues such as histidine, aspartate, and glutamate being changed in these 
mutations[269][356]. The question then emerges whether metal binding is impaired only in the free 
produced Aβ, or also in APP prior to APP cleavage, if the same site is accessible in the membrane-
bound APP before cleavage. Copper increases APP expression and Aβ formation via CUTA interaction 
with the β-cleavage site of APP[286]. The N-terminal metal site of Aβ, which is also the β-cleavage 
site, constitutes the actual site that regulates β-secretase cleavage of APP[288]. It is notable that Cu(II) 
and Zn(II) bind differently to Aβ, and Cu(II) binds more strongly[19][357], so binding of the two metal 
ions may also have different effects on APP cleavage. 
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If the metal binding capacity of Aβ is reduced by direct mutation, as is the case in N-terminal 
FAD mutants such as D7H[358] but not C-terminal CAA mutants such as A21G[359], it would reduce 
the peptide's normal function of metal export, to cause the observed cell toxicity. This mechanism 
would reconcile FAD-causing N-terminal Aβ variants with the more common PSEN1 phenotypes that 
cause depletion of functional Aβ by reduced catalytic cleavage of APP. Currently, the amyloid 
hypothesis does not reconcile these phenotypes, because the APP variants do not have the same general 
tendency of increasing the Aβ42/Aβ40 ratio as the PSEN1 mutants do[9]. It explains why the very 
different phenotypes of APP variants can all cause disease, which has not previously been explained: 
Notably, N-terminal Aβ variants that increase amyloid levels have impaired metal binding function, 
whereas the remaining variants increase aggregation propensity or affect APP cleavage by γ-secretase.  
 
The coupling to presenilin 
Any theory of AD pathology must explain not only the Aβ imbalances but also the important role of 
PSEN. As discussed above, almost 200 PSEN1 mutations and a smaller amount of PSEN2 mutations 
cause early-onset FAD; within the gain-of-function amyloid hypothesis, these are thought to be 
pathogenic by their effect on APP cleavage, which generally leads to an increase of the observed 
Aβ42/Aβ40 ratio[97][119]. However, PSEN1's own functions also receive attention[59][60][303], and γ-
secretase processes more than 20 other substrates, including Notch[360]. The number of PSEN1 
mutations vs. APP mutations and the distinct functions of PSEN1 outside the -secretase, among other 
facts, have inspired a hypothesis that AD is due to PSEN1 loss of function[59]. The most established 
function of PSEN is its involvement in calcium homeostasis, as summarized by the following 
observations: 
 i) PSEN1 is homologous to calcium transporters and has a ion-channel-like topology[243][361]. 
Recently, the structure of PSEN1-containing γ-secretase has been elucidated in substantial detail: The 
36 
 
3-dimensional structure of human γ-secretase was determined using single-particle cryo-electron 
microscopy[153][362], with PSEN having nine transmembrane helices resembling a barrel-like domain 
protecting the active site where two aspartates cleave APP in the membrane[153][360]. PSEN1 can 
work within the -secretase complex or without it[363][364]. 
 ii) Consistent with these structural features, PSEN1 works as a calcium channel independently 
of its role in -secretase activity[361][347][365]. Although a calcium-leak effect in the endoplasmic 
reticulum (ER) has been disputed by at least one group[366], the role of PSEN1 in calcium homeostasis 
of the ER is established[303][367][368]. PSEN1 mutations impair calcium homeostasis and show 
elevated calcium levels upon exposure to Aβ[348], and soluble APPα (sAPPα) fragment produced from 
APP restores calcium homeostasis and rescues PSEN1 mutant-exposed cells from apoptosis[369].  
 iii) PSEN1-knockout also causes loss of copper and zinc uptake and subsequent deficiency of 
these metal ions in brains of mice, leading to loss of superoxide dismutase 1 (SOD1) activity [346], the 
main antioxidant cytosolic copper-zinc protein that is also the main genetic risk factor of familial ALS 
[370][371].  
One of the main processes of cell turnover is the lysosomal degradation of cell parts including 
aggregated proteins in the cytoplasm by autophagy[372]; this clearance process is necessary for 
neurons to survive and is impaired in AD[367][373][374][375]. PSEN1 is important for lysosomal 
protein degradation and autophagy, which is impaired by FAD-causing PSEN1 mutations[376][377]. 
At the molecular level, PSEN1 helps to fold and glycosylate vacuolar ATPase that is essential for 
lysosome acidification and thus, activation of autophagy[376]; there is substantial evidence for a link 
between lysosomal failure in AD and calcium dyshomeostasis caused by PSEN1 dysfunction, as 
recently reviewed[367].  
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The role of apolipoproteins in copper/zinc homeostasis 
An accurate etiology of AD should also explain the important risk factor associated with the isoform 4 
of apolipoprotein E (ApoE4). Relevant to the presented hypothesis, González et al. found that serum 
levels of zinc, copper, and insulin are significantly higher in ApoE4 allele carriers[378]. Zinc 
deficiency also reduces expression of apolipoproteins[379], whereas copper deficiency has been found 
in several studies to increase apolipoprotein levels[380][381]. In transgenic mice carrying the ApoE4 
isoform, tau aggregation was modulated by zinc, i.e. zinc and ApoE4 work together to produce tau 
pathology[382]. These results show, from various points of view, important crosstalk between ApoE 
proteins and zinc and copper levels.  
 Also of interest in this context, clusterin (apolipoprotein J) has been shown to be upregulated 
upon zinc exposure[383]; this observation potentially relates clusterin, a risk factor of AD[69], to zinc-
dependent aging regulation. Clusterin has been found to work as a chaperone that regulates the turnover 
of copper ATPases that are central to brain copper homeostasis[384], as shown in several neurological 
diseases but perhaps best in Wilson's disease where mutations in these copper proteins directly cause 
disease[385]. Such mutations have indeed recently been related to ApoE4, as carriers of this isoform 
show earlier onset of Wilson's disease[386]. A consistent explanation of the various findings 
summarized above is that the lipoproteins are involved in the metal-transport function of Aβ. 
 
The Swedish mutation and why mice do not develop AD 
Whereas loss of function accounts for the therapeutic window of Aβ, the PSEN1 phenotypes and 
adverse outcomes of clinical Aβ-containment strategies, the gain-of-function amyloid hypothesis seems 
more consistent with the fact that some AD-causing APP mutations, notably the Swedish 
K670M/N671L double mutant[387], increase steady-state Aβ levels multiple times compared to wild 
type APP[388][389], potentially by enhancing the β-cleavage vs. α-cleavage of APP[352]. The 
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Swedish mutation was widely heralded as support of the early "quantitative" cascade hypothesis and is 
still used as a model of AD in mice[390][391].  
 However, several other AD-related APP mutations produce similar or reduced Aβ levels vs. 
wild type and heterogeneous phenotypes, and the Aβ42/Aβ40 ratio does not generally increase[9][388]. 
This makes the Swedish mutation phenotype-wise, and in terms of chemical effect on APP cleavage, 
very distinct from other APP mutations. Furthermore, the curious double-mutation has only ever been 
identified in a few families, making the genotype extremely rare. The combined rarity of phenotype 
and genotype renders the widespread use of this mutant as a transgenic mouse model of AD curious 
considering the amount of both APP and PSEN1mutant phenotypes that actually lower Aβ levels. The 
Swedish mutation increases total Aβ levels, but does not change the ratio, whereas most other mutants 
related to AD do the exact opposite.  
 Yet, the Swedish mutant does produce cognitive deficits when overexpressed in mice, how can 
this be reconciled with the hypomorphic PSEN1 phenotypes? One reasonable answer is that the 
Swedish mutant causes Aβ overproduction that causes the adverse effects by depleting intracellular 
metal status. Yankner et al.[171] already showed that there is a therapeutic window of Aβ 
concentrations. In this light, it is curious that noone has considered the possibility that the seemingly 
contradictory phenotypes of PSEN1 and Swedish mutants could be reconciled by this therapeutic 
window: In the former case, Aβ is depleted either by lowered production or increased oligomerization, 
in the latter case it is over-abundant and potentially aggregating, putting Aβ levels easily outside the 
healthy range in both cases. The suggested metal transport function rationalizes the observation of this 
this window.  
 Plaque load is substantially reduced if the zinc transporter ZnT3 is knocked out, showing that 
plaque formation depends on the function of zinc transport[392]. In contrast, ZnT3 knockout by itself 
gives age-dependent cognitive deficits in mice[308]. Overexpression of this mutant reduces SOD1 
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activity, a sign of copper deficiency, which could be remedied by copper exposure, showing that the 
Swedish mutant has a specific adverse effect on copper homeostasis in cells[282]; this effect can 
explain why the Swedish mutant gives AD in a way consistent with other mutants but unrelated to the 
high production of Aβ; i.e. while the APP cleavage is affected, other properties of the protein that relate 
to its copper homeostasis are affected too. 
 Why do cell/mouse FAD models give different results from human patient clinical trials? If the 
herein stated mechanisms are true, cell toxicity commonly measured upon expression of FAD mutants 
in cultured neurons and mice is due to extensive Aβ-metal export during overexpression of APP 
mutants and PSEN1 mutants. Incidentally, the normal wild-type mouse Aβ contains three different 
amino acids within the metal binding N-terminal: R5G, Y10F, and H13R. The host wild type Aβ is less 
toxic and less aggregation-prone than human Aβ and will modulate the amyloid pathology of such 
models unless it is knocked out[393]. Mouse Aβ still binds copper but differently from human 
Aβ[394]. It has been found that while copper binding and reduction is impaired in mouse Aβ due to 
these substitutions, the oxidative stress inducing effects have been found to be similar[395].  
 According to the arguments presented here, the transgenic mouse models relying on mutant 
overexpression cause Aβ production that lead to intra-neuronal metal depletion and impairment of the 
ability of synapses to maintain Cu/Zn/Ca gradients. In contrast, in actual humans suffering from FAD, 
the APP copy number is stable over long periods of time and lead to impaired metal export 
competence, because both PSEN1 mutants and APP mutants display reduced metal export capacity, 
and this causes intra-neuronal metal overload. This explanation is supported by the observation that 
zinc overload increases the extend of APP cleavage and extracellular metal-enriched Aβ deposits[351]; 
an impaired APP/Aβ system would be less capable of exporting metals and this would undermine 
Cu/Zn and Cu/Ca ratios, in particularly at high age when the brain is more exposed to oxidative stress 
and metal dyshomeostasis, according to quantitative proteomics studies of the aging human brain[38]. 
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These explanations are consistent with the mechanism suggested above, reconcile cell/mouse vs. 
human data, and link PSEN1 calcium transport function to APP/Aβ.  
  
 
 
Figure 7. APP cleavage and neuronal metal transport: A suggested mechanism of function. 
 
The tau connection 
As mentioned, filaments of hyper-phosphorylated tau, i.e. neurofibrillar tangles, constitute a prevailing 
histopathological feature of AD[23][41]. Normally, the protein associates with the microtubules and 
maintain cytoskeleton integrity. However, the phosphorylation is related to loss of tau from 
microtubules and formation of structures that are seen as tangles[396][397]. It is not clear how tau 
pathology relates to amyloid pathology, although various links have been suggested. However, 
aggregation of tau is, as most other proteins, triggered by post-translational modifications: As has been 
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recently shown, zinc-tau interactions fundamentally determine tau phosphorylation and tau 
toxicity[398], and free zinc induces tau phosphorylation[399] and aggregation[400]. Therefore, tau 
pathology can be an early feature of metal dyshomeostasis[46][382], and tau hyperphosphorylation and 
aggregation may increase as  cytoskeletons are dismantled during controlled cell death in the stage of 
neurodegeneration in a deteriorating vicious cycle of increased oxidative stress, metal imbalances, tau 
and amyloid pathology that reinforce each other[19].  
 
Loss of function is consistent with Aβ-related biomarkers of disease 
Two of the five most commonly used biomarkers of AD relate directly to Aβ, i.e. the measurement of 
Aβ42 levels in the cerebrospinal fluid, and Positron Emission Tomography (PET) Aβ imaging[111]. 
However, the idea that these biomarkers relate to gain of toxic Aβ is an assumption, and below it is 
argued that these biomarkers more suitably indicate loss of Aβ function. 
 Amyloid deposits build up gradually over many years in AD[401], and positive PET imaging of 
Aβ deposits usually accompanies AD diagnosis[18][402]. However, as discussed above, plaque 
deposits are no longer considered the pathogenic feature of AD, both because many cognitively normal 
people have such deposits[108][109][110], because deposition does not correlate with cognitive 
decline[106][107], because aggregation tendencies of Aβ variants do not correlate with clinical 
severity[9], and because plaques, which are extracellular insoluble deposits of Aβ, are not very toxic, 
whereas intracellular soluble oligomers of Aβ are[112][113][114][115][116]. In contrast, a high plaque 
load may in some people indicate protective ability to export pathogenic forms of Aβ from 
cells[117][118]. The deposits may still represent pre-clinical disease states[111], and the PET imaging 
will continue to provide valuable information on amyloid balance, but its relationship to amyloid gain 
of toxic function etiology is not evident. Instead, since these deposits are not molecularly active inside 
the neurons, they primarily indicate that neuronal Aβ balance is disturbed, or more specifically, I argue 
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that they indicate a depletion of functional monomers inside neurons as a result of depositing of Aβ in 
plaques. 
 Similarly, reduced Aβ42 in the cerebrospinal fluid is a useful biomarker of AD that correlates 
strongly to positive PET imaging discussed above[111]. In early-onset FAD, Aβ42 levels were reduced 
already 25 years before cognitive symptoms[403]. The inverse correlation between Aβ42 in the 
cerebrospinal fluid and extracellular insoluble plaque deposits from PET imaging[404] strongly 
indicates that the soluble pools of Aβ42 have been depleted in favor of the deposits; since the deposits 
are not pathogenic, depletion of soluble Aβ42 seems consistent with loss of soluble Aβ from the 
neurons, i.e. if the overall soluble pool of functional Aβ has been depleted in favor of non.functional 
oligomers and aggregates. In contrast, surplus of soluble intracellular Aβ42 oligomers as argued by the 
more recent versions of the gain-of-function hypothesis is not directly commensurable with this 
depletion, because as oligomers belong to soluble pools, they would be expected to be in equilibrium 
with cerebrospinal fluid levels. The temporal ordering of biomarker output[111][405] is thus consistent 
with a gradual loss of the functional monomer pool, caused by increased demand for the peptide due to 
neuronal age-dependent stress, including metal dyshomeostasis, and due to the removing of monomers 
by continuous Aβ aggregation over time. 
  
Relation to the main clinical outcome, memory loss 
How does the suggested APP/Aβ divalent metal transport system relate to neuronal signaling and 
memory loss? As has been known for 25 years, AD is particularly characteristic by the loss of synapses 
rather than merely neurons[406][407]. The cholinergic hypothesis has for many years reflected the 
direct impairment of forebrain pathways of the acetylcholine-rich neurons involved in attention and 
working memory[49][50] but was challenged by its weaker association with histopathology and genetic 
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risk factors[408]. The evidence for a physiological function of the APP/Aβ system in signaling is as 
follows:  
 First, APP localizes in the pre- and postsynaptic compartments and is expressed in 
glutamatergic neurons, and NMDA receptor activation reduces Aβ production by activation of α-
secretases, the zinc peptidases that cleave APP within the Aβ region to prevent Aβ 
production[114][409] (different previous results could be explained by transcriptional regulation upon 
prolonged NMDA receptor stimulation[409]). NMDA receptor activation is characterized by the 
channeling of metal ions through the neuron membrane, directly relating Aβ to this function that is 
essential for synaptic plasticity and memory[410][411].  
 Second, synapses are targeted by Aβ[412] and synaptic structure is affected by Aβ[413]; this 
could be a mode of toxicity, as has been suggested[414], but given the peptide's natural functions, co-
location with synapses could equally well be a result of Aβ's normal function. This is supported by 
findings that Aβ regulates vesicle release in hippocampal synapses, with extracellular Aβ proportional 
to release probability[169]. Again, the concentration range in vesicles becomes critical, as the 
therapeutic window between neurotropic and toxic features is narrow[171].  
 These findings are consistent with the function suggested above, i.e. that Aβ is involved in 
divalent metal cross-membrane transport during neuronal signaling, as also implied by the findings of 
Ramsden et al.[276][415]. This function would immediately explain the need for a delicate balance of 
Aβ levels, as argued by Pearson and Peers[168], as such a balance parallels the delicate homeostasis of 
metal ions: Indeed, Abramov et al. found that short-term synaptic facilitation required balanced Aβ 
levels, as impairment resulted from both too high and too low levels of Aβ[169]. Synaptic activity 
requires the repeated flow of glutamate, calcium, and zinc in order to enable neuron signaling and 
memory formation [19][28][279][328], providing the rationale for such a function of Aβ in synapses.  
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Oxidative stress, proteostasis, metabolism, and mitochondria  
Oxidative stress is a general feature of AD; most affected tissue bears signs of massive oxidative stress 
in the form of oxidized proteins and lipids[48][416]. Oxidations of proteins also affect protein turnover 
by modifying the surfaces of proteins and subjecting them to proteolysis[417]. The importance of 
protein turnover in AD and related neurodegenerative diseases is evident not just from the protein 
misfolding characteristic to these diseases, but also from risk factors relating to protein quality 
control[129]. It is notable that calcium play a key role in proteostasis regulation, and several regulators 
of proteostasis work by inhibiting calcium channels to decrease cytoplasmic calcium levels, which 
upregulate protein quality control machinery[129]. 
Protein misfolding also plays a main role in ALS, although the pathogenic mechanism of the 
misfolded proteins remains unclear[418]. However, recently, it was shown that survival times of 
patients carrying a mutation in SOD1 correlate inversely with the energy cost of turnover of the 
particular SOD1 mutant[281]. This energy increase is typically caused by loss of stability and increased 
aggregation due to mutation or post-translational modification, but also depends on protein copy 
number and specific turnover costs that may play out within the RNA pool[419]. This suggests that 
neurodegenerative diseases may be caused by neuronal energy deficiency at least partly owing to 
increased protein turnover; if so, misfolded proteins do not cause disease by some molecular toxic 
mode, but rather indirectly via their burden on systemically available neuron maintenance energy[281].  
AD has been viewed by some as a mitochondrial disease[139][140][141][142][420], and Aβ 
can accumulate in mitochondria and interact with inner mitochondrial membranes where neuron energy 
is produced[139]. As discussed above, the evidence of Aβ as a small metal-binding[19][31][248] 
membrane-interacting[135][207] peptide seems strongly supported by its chemical amphiphilic nature 
and its conformational features[9][213]. Aβ causes permeabilization of cell membranes by channel 
formation[133][135][277][278][279]. The resulting calcium dyshomeostasis is massively 
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documented[29][30][137][242][421]. If APP/Aβ controls secondary metal ion balances, then its 
impairment would compromise metal homeostasis. Metal ion dyshomeostasis is a two-edged short in 
terms of energy: Loss of functional bound metal pools undermines the proteostatic machinery and 
prevents refolding of metalloproteins, which increases proteome maintenance costs due to increased 
protein turnover[281]. In addition, the imbalances in metal pools will most likely increase ion-pump 
energy costs as well. Protein turnover and ion gradient maintenance are the two main energy requiring 
processes of cells[419]. The increased demand for neuronal energy will put strain on mitochondria and 
cause pathological changes, increased ROS production, and plausibly, once the neuron maintenance 
energy requirements can no longer be met, apoptosis of the neurons in question. These neurons are, 
incidentally, often the most energy demanding and metal-enriched cells of the hippocampus where AD 
often initiates. 
Thus, it is not surprising that neurons, among the most energy-requiring cells of the body, are 
particularly sensitive to protein misfolding, oxidative stress and metal dyshomeostasis: In the "energy 
hypothesis" of neurodegerative diseases[281], the known metabolic features of these diseases can be 
coupled to the protein misfolding and explain why these diseases occur specifically in neurons, where 
allocation of energy to ion pumps is particularly required. Neuronal exhaustion will be endangered by 
chemical aging, as seen in the upregulation of proteins relating to exactly anti-stress function, calcium-
regulation, and fatty acid metabolism in aging human brains[38]. Such pathology would be fueled by 
metal ion dyshomeostasis caused by ineffective APP/Aβ/PSEN1 divalent metal transport resulting from 
FAD-related mutations, both in terms of the increased cost of ion pumping and because metal 
dyshomeostasis increases misfolding of metalloproteins central to AD[19]; this is possibly the reason 
why APP and PSEN mutations cause AD in earlier age as the energy threshold that triggers neuron 
death will be reached earlier.  
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Thus, SAD and FAD can be unified within the loss of function mechanism. In contrast, within 
the amyloid hypothesis, it is unclear how SAD arises by accumulation of pathogenic Aβ oligomers and 
how aging triggers AD.  
 
Perspectives on diagnosis and treatment of AD 
AD needs to be diagnosed as early as possible to enable timely treatment that can prolong life-
span[403]. At the time that patients are diagnosed, disease progression already prevents major 
improvements in prospects[37][403][422]. As argued previously[19], since this disease represents an 
imbalance gradually aggravated by aging processes, the only viable biomarkers are abundance ratios 
that quantify relative levels of the chemical species involved in disease progression. Markers of 
accelerated chemical aging such as e.g. early oxidative stress or lipid metabolism should be combined 
with markers such as Aβ42/Aβ40, Cu/Aβ40, and Ca/Aβ40. Also, tissue-specific Cu/Zn and Cu/Ca vs. 
healthy controls may be relevant markers of the metal dyshomeostasis that is suggested to cause AD. 
 In addition to the development of effective early biomarkers based on chemical aging and metal 
homeostasis perturbations, a treatment should address the imbalances described in this review. Given 
the presented mechanism of disease, it is not particularly surprising that Mediterranean diets and active 
life styles reduce risk of AD[84][91][92]. Obviously, such risk modifiers should be actively applied in 
treatment strategies; anything else would be neglect of the available tools to secure optimal patient life 
quality. While we do not know the active ingredients in all cases, a healthy and varied diet with 
vegetables, olives, and fish, green tea, coffee and curry is known to reduce AD risk[92][423]. Such a 
diet should be complemented by effective medicine if possible, which, according to the mechanisms 
suggested in this review, should have as a strategy to rebalance Aβ levels rather than deplete them 
entirely; the latter strategy has so far failed, as discussed above. Based on the evidence provided here, 
Aβ balancing would be a key aspect of a treatment strategy. It could further be combined with anti-
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inflammatory hormone treatment and possibly additional zinc and anti-oxidant vitamin supplements. 
When combined with a carefully monitored treatment strategy pursuing an active cognitive life-style, 
this would, in this author's opinion, provide the best possible multi-factor treatment strategy of this 
terrible disease, although much research will clearly be needed to identify the most relevant compounds 
in such a strategy. 
 
Concluding remarks 
In this review, the anomalies and inconsistencies of the current version of the amyloid hypothesis have 
been addressed in an attempt to provide a fully consistent etiology of AD. This etiology centers on the 
identification of the normal physiological function (a natural role has already been implied by many 
lines of research) of the APP/Aβ system and PSEN all related to maintaining relative metal ion levels 
within the neuron. These metal balances, notably the Cu/Zn and Cu/Ca ratios, are clearly affected by 
these proteins as seen from multiple studies. Impairment of the function of these proteins is then argeud 
to be the cause of early-onset familial AD, and this enables a unification, not only of the amyloid, 
oxidative stress, and metal ion hypothesis of AD, but also of the sporadic and familial forms of disease, 
as discussed in the latter part of the review.  
 The loss-of-function etiology of AD provides solutions to inconsistencies that are not currently 
accounted for by the gain-of-function amyloid hypothesis that dominates the field. It also has 
substantially more explanatory power while preserving the role of Aβ aggregation, not as a pathogenic 
mode of action, but as a loss of the functional Aβ monomers. The gain-of-function amyloid hypothesis, 
without a function clarified, provides a link to the genetic risk factors APP and PSEN1 and PSEN2, but 
not to the main genetic risk factor of SAD, ApoE4, and the main risk factor of AD, age. With a 
function clarified, all these features can be understood in context. Notably, the amyloid deposits often 
taken to indicate overload are interpreted instead here as a sign of intracellular functional monomer 
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deficiency. To prove this theory, the extracellular and intracellular Aβ pools must be separated into 
their various types, to test whether Aβ levels are indeed deficient inside neurons of people with AD. 
The loss of function hypothesis explains clinical failures of Aβ reducing drugs and why inhibition or 
depletion of A40 by either secretase inhibitors or A antibodies is lethal to cultured neurons[235], and 
the findings that Aβ depletion impairs neuronal activity in mice[166]. Thus, new drug strategies should 
center on balancing and reconstituting functional monomers rather than strict reduction. 
 The synthesis provided in this review is not intended to be final; nor is it anywhere close to 
providing a full detail of the biochemical complexity of this major disease. However, it is the hope of 
the author that the proponents of different theories on the etiology of AD will see this attempt at a 
synthesis as a welcome bridging between camps and fields; given the complexity of this disease, such 
bridging is urgently needed, as is the working together of scientists across disciplines, if we are ever to 
conquer and defeat this terrible form of dementia that affects so many millions of people today. 
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